Founded in 2002, ACEA Biosciences, Inc. (ACEA) is a pioneer in the development and commercialization of high performance, cutting edge cell analysis platforms for life science research. ACEA’s xCELLigence® impedance-based, label-free, real-time cell analysis systems and NovoCyte™ benchtop flow cytometers are used in preclinical drug discovery and development, toxicology, safety pharmacology, disease studies, and basic academic research.
Employing noninvasive microelectrodes in automated high-throughput plate formats, our xCELLigence Real-Time Cell Analysis (RTCA) systems maximize the physiological relevance of data extracted from in vitro cellular assays by enabling label-free, real-time monitoring of cell proliferation, invasion/migration, and morphological change. By eliminating the time- and labor-intensive steps of traditional methods, RTCA vastly improves efficiency and overall productivity. Moreover, by continuously providing data on cell growth and morphology in the short (minutes to hours) and long (days to weeks) time regimes, RTCA provides a phenotypic view of cellular behavior at an unprecedented level of detail. Our RTCA systems operate within standard cell culture incubators and are currently being used worldwide in industrial and academic labs in applications that include, but are not limited to, the following:
-Long-term Cardiotoxicity Effects
ACEA is also helping to revolutionize the field of flow cytometry by designing and producing high performance, customizable benchtop machines at accessible price points. By including the below features, ACEA’s line of Novocyte™ flow cytometers is raising the bar for what is expected of benchtop machines.